Skip to main content
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. logo

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings

Ticker · 688238 ISIN · CNE1000059N9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 486 across all filing types
Latest filing 2022-04-26 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688238

About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.

https://www.obio-tech.com/

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.

Recent filings

Filing Released Lang Actions
2022年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022 年第一季度报告' which translates to '2022 First Quarter Report'. It contains detailed financial data including consolidated balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2022. The report explicitly states it is unaudited and covers a period shorter than a full fiscal year (quarterly). The presence of comprehensive financial statements and analysis confirms it is an Interim / Quarterly Report. There is no indication that this is merely an announcement or a certification, and the document length (15,000 characters) supports it being a full report rather than a brief notice. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2022
2022-04-26 Chinese
关于使用自有闲置资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the company about the use of its own idle funds for cash management. It includes details about the investment purpose, amount, risk analysis, and board approval. The document is relatively short (1680 characters) and does not contain financial statements or detailed financial data. It is a regulatory announcement about a financing or capital management activity rather than a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP).
2022-04-22 Chinese
第二届监事会第十八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company regarding various agenda items including the 2021 Supervisory Board Work Report, 2021 Financial Final Report, 2022 Financial Budget Report, profit distribution plan, audit firm reappointment, related party transactions, cash management proposals, and remuneration plans for 2022. The document contains meeting details, voting results, and references to reports and announcements that will be submitted to the shareholders' meeting for approval. The document itself is a formal announcement of meeting resolutions rather than the full reports or financial statements. It is relatively short (3219 characters) and does not contain detailed financial data or full reports but summarizes decisions and approvals. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement of supervisory board meeting resolutions and related corporate governance matters, not the full annual report, audit report, or financial statements themselves.
2022-04-22 Chinese
和元生物技术（上海）股份有限公司独立董事关于第二届董事会第二十四次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from independent directors regarding various company matters such as profit distribution, audit firm reappointment, related party transactions, cash management, remuneration, and board member changes. It references compliance with company law and internal regulations, and it is intended to support proposals to be submitted to the shareholders' meeting. The document does not contain financial statements or detailed financial data but rather expresses independent directors' opinions on governance and corporate actions. It is not a full annual report, audit report, or earnings release. It is also not a simple announcement of a report publication. The content aligns with governance-related disclosures and opinions on board and management matters. Therefore, the best fitting category is Board/Management Information (MANG). The document length is short (2110 characters), consistent with an opinion letter rather than a full report.
2022-04-22 Chinese
海通证券股份有限公司关于和元生物技术（上海）股份有限公司预计2022年度日常关联交易事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed opinion and verification report from Haitong Securities regarding the expected 2022 annual related party transactions of Heyuan Biotechnology (Shanghai) Co., Ltd. It includes transaction amounts, related parties, approval procedures, and independent directors' opinions. The document is not an annual report, earnings release, or financial statement but rather a regulatory or compliance-related verification report concerning related party transactions. It does not announce voting results or changes in management, nor is it a proxy or capital change announcement. The document is also not a certification or a short announcement but a substantive verification opinion. Given the nature of the content and the regulatory context, this fits best under Regulatory Filings (RNS), which covers compliance documents and miscellaneous filings that do not fit other categories.
2022-04-22 Chinese
和元生物技术（上海）股份有限公司独立董事关于第二届董事会第二十四次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal statement from independent directors providing prior approval opinions on matters to be discussed at the company's board meeting, specifically regarding the reappointment of the 2022 audit firm and anticipated related party transactions for 2022. It references the company's articles, laws, and internal rules, and is dated April 20, 2022. The content is about board-level approvals and opinions rather than a full audit report or annual report. It does not contain financial statements or detailed audit results but is related to board/management decisions and approvals. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on management/board opinions, not a full report or announcement of a report publication.
2022-04-22 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.